Dr. Martens plc (LON:DOCS – Get Free Report) insider Giles Wilson acquired 269 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was acquired at an average cost of GBX 56 ($0.73) per share, with a total value of £150.64 ($195.03).
Giles Wilson also recently made the following trade(s):
- On Tuesday, February 11th, Giles Wilson purchased 207 shares of Dr. Martens stock. The shares were acquired at an average cost of GBX 73 ($0.95) per share, with a total value of £151.11 ($195.64).
- On Monday, January 13th, Giles Wilson acquired 222 shares of Dr. Martens stock. The stock was bought at an average cost of GBX 68 ($0.88) per share, for a total transaction of £150.96 ($195.44).
Dr. Martens Stock Up 1.3 %
Shares of LON DOCS traded up GBX 0.70 ($0.01) on Wednesday, hitting GBX 54.85 ($0.71). The company had a trading volume of 1,714,085 shares, compared to its average volume of 3,107,159. The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27. Dr. Martens plc has a 12-month low of GBX 49.32 ($0.64) and a 12-month high of GBX 99.40 ($1.29). The firm has a market capitalization of £532.46 million, a P/E ratio of 7.78, a PEG ratio of 6.40 and a beta of 0.11. The business has a 50 day moving average of GBX 68.93 and a two-hundred day moving average of GBX 64.88.
Dr. Martens Cuts Dividend
About Dr. Martens
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Featured Articles
- Five stocks we like better than Dr. Martens
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Insider Trading – What You Need to Know
- Why Energy Transfer Belongs on Your Watchlist
- Buy P&G Now, Before It Sets A New All-Time High
- Why Wayfair Stock May Be a Hidden Gem for Value Investors
Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.